Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | SQLE | Q14534 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635912 | 1.00 | KDM4E (0.62) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL635911 | 1.00 | KDM4E (0.62) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL9243080 | 0.98 | KMT2A (0.61) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL16977628 | 0.98 | KMT2A (0.61) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL16892779 | 0.98 | KMT2A (0.61) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL9245593 | 0.98 | KMT2A (0.61) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL16892778 | 0.98 | KMT2A (0.61) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL25244004 | 0.84 | KDM4E (0.59) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL10707381 | 0.84 | KDM4E (0.46) | KDM4EKMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL27090456 | 0.82 | KMT2A (0.57) | KDM4EKMT2AMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102850227-B | Prochiral allyl amine compound and synthetic method thereof | SYNERGETICA CHANGZHOU CHEMICAL CO LTD | 2015-05-13 | — | — | CN | claimed |
| CN-102850227-A | Prochiral allyl amine compound and synthetic method thereof | SYNERGETICA CHANGZHOU LTD | 2013-01-02 | — | — | CN | claimed |
| EP-1060793-B1 | Stereospecific isomerisation of allylamines with the aid of immobilised phosphorated chiral ligands | FIRMENICH & CIE (CH) | 2005-06-15 | — | — | EP | claimed |
| EP-0949241-B1 | Stereospecific isomerisation of allylic amines using chiral phosphorus ligands | FIRMENICH & CIE (CH) | 2003-12-10 | — | — | EP | claimed |
| US-6350910-B1 | ISOMERIZATION OF ALLYLAMINES TO VINYLAMINES AND IMINES WITH PHOSPHINE LIGANDS | FIRMENICH SA (CH) | 2002-02-26 | — | — | US | claimed |
| EP-1060793-A1 | Stereospecific isomerisation of allylamines with the aid of immobilised phosphorated chiral ligands | FIRMENICH SA (CH) | 2000-12-20 | — | — | EP | claimed |
| US-6020527-A | Stereospecific isomerisation of allyl amines using chiral phosphorous ligands | FIRMENICH SA (CH) | 2000-02-01 | — | — | US | claimed |
| EP-0949241-A2 | Stereospecific isomerisation of allylic amines using chiral phosphorus ligands | FIRMENICH SA (CH) | 1999-10-13 | — | — | EP | claimed |
| EP-0012224-B1 | PROCESS FOR THE SYNTHESIS OF FRAGRANT MIXTURES | L. Givaudan & Cie Société Anonyme (CH) | 1989-01-18 | — | — | EP | claimed |
| US-4266087-A | Process for preparing a myrcenol, cis-ocimenol mixture substantially free of trans-ocimenol | GIVAUDAN CORPORATION (US) | 1981-05-05 | — | — | US | claimed |
| JP-4026646-A | — | — | None | — | — | JP | disclosed |
| US-20260015572-A1 | MICROORGANISMS AND METHODS FOR THE CONTINUOUS PRODUCTION OF FATTY ACID DERIVED PRODUCTS THROUGH THE EXPRESSION OF 3-HYDROXYACYL-ACP:COA TRANSACYLASES | LANZATECH INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250353805-A1 | PROCESS | GIVAUDAN SA (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12371727-B2 | Microorganisms and methods for the continuous co-production of tandem repeat proteins and chemical products from C1-substrates | LANZATECH, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025128744-A1 | STRAINS AND METHODS FOR THE CONTINUOUS PRODUCTION OF PRODUCTS BY GAS FERMENTATION | LANZATECH, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-4266087-A | Process for preparing a myrcenol, cis-ocimenol mixture substantially free of trans-ocimenol | GIVAUDAN CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| US-4244890-A | PREPARED BY CYCLIZATION OF NERYL AND GERANYL AMINES | SCM CORPORATION (US) | 1981-01-13 | — | — | US | disclosed |
| US-4186148-A | Process for producing 3,7-dimethyl-2,6-octadienylamine derivatives | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 1980-01-29 | — | — | US | disclosed |
| US-4179468-A | Cyclic terpenoid onium salts, their preparation and uses | SCM CORPORATION (US) | 1979-12-18 | — | — | US | disclosed |
| US-4107219-A | OXIDIZING UNSATURATED AMINE, THERMAL REARRANGEMENT TO FORM UNSATURATED HYDROXYLAMINE, HYDROGENATION | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015572-A1 | MICROORGANISMS AND METHODS FOR THE CONTINUOUS PRODUCTION OF FATTY ACID DERIVED PRODUCTS THROUGH THE EXPRESSION OF 3-HYDROXYACYL-ACP:COA TRANSACYLASES | COASY, FADS2, FADS1 | KDM4E 1096/4885KMT2A 1601/4885MEN1 3732/4885 |
| US-20250353805-A1 | PROCESS | DEGS1, FDFT1, SQLE | KDM4E 696/4885KMT2A 3167/4885MEN1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.